Cancer guide
By Cura Editorial Team ·
Often called silent, but the symptoms are real and specific — bloating, pelvic pressure, and feeling full fast. BRCA and HRD testing now shape treatment for almost every patient.
Recent approvals and trial results — and the questions to ask your oncologist about whether any of it applies to you. Not every option fits every person.
Based on the phase 3 KEYNOTE-B96 trial, the FDA approved pembrolizumab with chemotherapy for platinum-resistant ovarian cancer that tests PD-L1-positive.
May apply to: Platinum-resistant, PD-L1-positive ovarian cancer
Ask your oncologist:
Source: FDA
In the phase 3 ROSELLA trial, relacorilant (Lifyorli) with chemotherapy lowered the risk of death by 35% in platinum-resistant ovarian cancer; no biomarker test is required.
May apply to: Platinum-resistant ovarian, fallopian tube, or peritoneal cancer
Ask your oncologist:
Source: Corcept Therapeutics
Reviewed September 25, 2026.
Email me when something new is approved for ovarian cancer
Only real treatment news for this cancer, in plain language. Optional — the guide and Ask Cura stay free and anonymous. Unsubscribe anytime.
The signs that most often lead to a ovarian cancer diagnosis are: persistent bloating, pelvic or abdominal pain lasting more than 2–3 weeks; feeling full quickly or a new change in appetite; urinary urgency or frequency without an infection. Any of these lasting more than a couple of weeks is worth a same-week appointment, even though most turn out to be something else.
See a doctor promptly if a symptom is new, persistent, or getting worse rather than better. Describe when it started, how often it happens, and what makes it better or worse — that detail is what decides whether you get imaging or testing at the first visit.
Often called silent, but the symptoms are real and specific — bloating, pelvic pressure, and feeling full fast. BRCA and HRD testing now shape treatment for almost every patient. There is no reliable screening test — symptom awareness is the earliest signal. BRCA1/2 and HRD (homologous recombination deficiency) testing determines PARP-inhibitor eligibility. A gynecologic oncologist (not a general gyn) should lead surgery — outcomes are meaningfully better.
Ask what the exact diagnosis is and how it is staged, what the treatment options are and in what order they would happen, what the goal of treatment is, which side effects to expect, and whether a second opinion or clinical trial makes sense for your situation.
Paste a pathology report, upload a scan summary, or just type the question you'd ask your oncologist if you had more than 15 minutes. Cura will answer in plain language.
Ask CuraWant occasional plain-language health explainers?
A short note now and then. No spam, unsubscribe anytime.
If a start date is on the calendar, or you feel lost between diagnosis and the first infusion, build a first-visit brief on the page: what's known, what's missing, what to ask. Homework, not a treatment plan.
Cura Brief is educational. It is not medical advice, a diagnosis, or a treatment plan. Confirm everything with your oncology team. If this is an emergency, call emergency services. Email is not an emergency line.
Prefer email? hello@curawellplan.com
Waiting for results is its own kind of hard. Cura has a plain-language guide to what the wait actually means — and what to do while you wait.
How long do biopsy results take?